Skip to main content
SpringerLink
Log in

The mode of action of azapropazone in relation to its therapeutic actions in rheumatic conditions and its major side-effects

  • Chapter
Azapropazone

Abstract

Azapropazone* is a moderately potent anti-inflammatory analgesic agent when compared, on a dose-for-weight basis in animal models and man, with standard drugs, such as aspirin, indomethacin and Phenylbutazone1,2. In some of the standard acute and chronic animal models of inflammatory conditions, the potency of azapropazone is between that of ibuprofen and Phenylbutazone1,2 (see Tables 1 and 2). In man, the dose range for the control of pain and inflammation in most rheumatic diseases is 1200–1800 mg daily1. At this dose, its efficacy is roughly comparable to most other nonsteroidal anti-inflammatory drugs (NSAIDs) at their respective recommended daily doses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Walker, FS (1985). Azapropazone, and related benzotrianzes. In: Rainsford, KD (ed), And-Inflammatory and Anti-Rheumatic Drugs, Vol. II. (Boca Raton, FL.: CRC Press), pp. 1–32

    Google Scholar 

  2. Rainsford, KD, Davies A, Mundy, L and Ginsburg, I (1989). Comparative effects of azapropazone on cellular events at inflamed sites. Influence on joint pathology in arthritic rats, leucocyte Superoxide and eicosanoid production, platelet aggregation, synthesis of cartilage proteoglycans, synovial production and actions of interleukin-1 in cartilage resorption correlated with drug uptake into cartilage in-vitro. J Pharm Pharmacol, 41, 322–30

    Article  PubMed  CAS  Google Scholar 

  3. Rainsford, KD (1989). Concepts of the mode of action and toxicity of anti-inflammatory drugs. A basis for safer and more selective therapy, and for future drug developments. In: Rainsford, KD and Velo, GP (eds), New Developments in Anti-Rheumatic Therapy. (Lancaster, UK: Kluwer Academic Publishers), pp. 37–92

    Chapter  Google Scholar 

  4. Famaey, J-P (1987). Synovial anti-inflammatory and anti-rheumatic drug levels: importance in therapeutic efficacy. In: Lewis, AJ and Furst, DE (eds), Nonsteroidal Anti-Inflammatory Drugs, Mechanisms and Clinical Use. (New York & Basel: Marcel Dekker), pp. 201–14

    Google Scholar 

  5. Kitchen, EA, Dawson, W, Rainsford, KD and Cawston, T (1985). Inflammation and possible modes of anti-inflammatory drugs. In: Rainsford, KD (ed), Anti-Inflammatory and Anti-Rheumatic Drugs, Vol. I. (Boca Raton, FL: CRC Press), 21–87

    Google Scholar 

  6. Lewis, AJ and Furst, DE (eds) (1987). Non-steroidal Anti-Inflammatory Drugs. Mechanisms and Clinical Use. (New York & Basel: Marcel Dekker)

    Google Scholar 

  7. Paulus, HE, Furst, DE and Dromgoole, SH (eds) (1987). Drugs for Rheumatic Disease. (New York: Churchill Livingstone)

    Google Scholar 

  8. Anon (1987). Which NSAID? Drug Therapeutics Bulletin, 25, 21

    Google Scholar 

  9. Jahn, U and Adrian, RW (1969). Pharmakoligische und toxikologische Prüfung des neuen Antiphogisticums Azapropazon = 3-Dimethylamino-7-methyl-1-2-(2-propylmalonyl)-1, 2-dihydro-1, 2, 4-benzo-triazin. Arzneim-Forsch, 19, 36–52

    CAS  Google Scholar 

  10. Jahn, U and Wagner-Jauregg, Th (1974). Wirkungsvergleich sauer Antiphlogistika im Bradykinin-, UV-Erythem-und Rattenpfotenödem-Test, Arzneim-Forsch, 24, 494–9

    CAS  Google Scholar 

  11. Dawson, W (1979). Models of acute inflammation — a commentary. In: Rainsford, KD and Ford-Hutchinson, AW (eds). Prostaglandins and Inflammation AAS6. (Basel: Birkhauser), pp. 83–9

    Google Scholar 

  12. Militzer, K and Hirche, H (1981). Prophylaktische und therapeutische Anwendung von Antiphlogistika — untersucht am Carrageenin — Pfotenödem der Ratte. Arzniem-Fosch, 31, 26–32

    CAS  Google Scholar 

  13. DiRosa, M and Sorrentino, L (1970). Some pharmacodynamic properties of carrageenin in the rat. Br J Pharmacol, 38, 214–20

    CAS  Google Scholar 

  14. DiRosa, M, Papadimitriou, JM and Willoughby, DA (1971). A histopathological and pharmacological analysis of the mode of action of non-steroidal anti-inflammatory drugs. J Path, 105, 239–56

    Article  CAS  Google Scholar 

  15. Bolam, JP, Elliott, PNC, Ford-Hutchinson, AW and Smith, MJH (1974). Histamine, 5-hydroxytryptamine, kinins and the anti-inflammatory activity of human plasma fraction in carrageenan-induced paw oedema in the rat. J Pharm Pharmacol, 26, 434–40

    Article  PubMed  CAS  Google Scholar 

  16. Vinegar, R, Truax, JF and Selph, JL (1976). Quantitative studies on the pathway to acute carrageenan inflammation. Fed Proc, 35, 2447–56

    PubMed  CAS  Google Scholar 

  17. Willis, AL (1970). Identification of Prostaglandin E2 in rat inflammatory exudate. Pharmacol Res Commun, 2, 297–304

    Article  CAS  Google Scholar 

  18. Blackham, A, Norris, AA and Woods, FAM (1985). Models for evaluating the anti-inflammatory effects of inhibitors of arachidonic acid metabolism. J. Pharm Pharmacol, 37, 787–93

    Article  PubMed  CAS  Google Scholar 

  19. Thompson, AW, Fowler, EF and Pugh-Humphreys, RGP (1979). Review/commentary. Immunopharmacology of the macrophage toxic agent carrageenan. Int J Immunopharmacol, 1, 247–61

    Article  Google Scholar 

  20. Thompson, AW and Fowler, EE (1981). Carrageenan: A review of its effects on the immune system. Agents & Actions, 11, 265–73

    Article  Google Scholar 

  21. Vinegar, R, Schrieber, W and Hugo, R (1969). Biphasic development of carrageenan edema in rats. J Pharmacol Expt Therap, 266, 96–103

    Google Scholar 

  22. Gemmell, DK, Cottney, J and Lewis, AJ (1979). Comparative effects of drugs on four paw oedema models in the rat. Agents & Actions, 9, 107–16

    Article  CAS  Google Scholar 

  23. Moncada, S, Ferriera, SH and Vane, JR (1975). Inhibition of Prostaglandin synthesis as a mechanism of analgesia of aspirin-like drugs in the dog knee joint. Europe J Pharmacol, 31, 250–60

    Article  CAS  Google Scholar 

  24. Juan, H and Lembeck, F (1976). Release of Prostaglandins from the isolated perfused rabbit ear by bradykinin and acetylcholine. Agents & Actions, 6, 642–5

    Article  CAS  Google Scholar 

  25. Otterness, IG, Wiseman, EH and Gans, DJ (1979). A comparison of the carrageenan edema test and ultraviolet light-induced erythema test as predictors for the clinical dose in rheumatoid arthritis. Agents & Actions, 9, 177–83

    Article  CAS  Google Scholar 

  26. Woodward, DF, Rowal, P, Pipkin, MA and Owen, DAA (1981). Re-evaluation of the effect of non-steroidal anti-inflammatory drugs on U.V.-induced cutaneous inflammation. Agents & Actions, 11, 711–7

    Article  CAS  Google Scholar 

  27. Winter, CA and Nuss, GW (1966). Treatment of adjuvant arthritis in rats with anti-inflammatory drugs. Arth Rheum, 9, 394–404

    Article  CAS  Google Scholar 

  28. Maeda, M, Tanaka, Y, Suzuki, T and Nakamura, K (1979). Pharmacological studies on carprofen, a new non-steroidal anti-inflammatory drug, in animals. Folia Pharmacol Japon, 73, 757–77

    Article  Google Scholar 

  29. Lewis, DA, Best, R and Bird, J (1977). Anti-inflammatory action of azapropa-zone. J Pharm Pharmacol, 29, 113–4

    Article  PubMed  CAS  Google Scholar 

  30. Szanto, L, Tanka, D and Kellner, M (1976). Inhibitions of Prostaglandin potentiated formalin induced arthritis with non steroid antiphlogistics. Int J Clin Pharmacol, 13, 113–9

    CAS  Google Scholar 

  31. Jahn, U, Relier, J and Schatz, F (1973). Pharmacokinetische Untersuchungen mit Azapropazon bei Tieren. Arzneim-Forsch, 23, 660–6

    CAS  Google Scholar 

  32. Ackerman, NR, Rooks, WH, Shott, HL, Genant, H, Maloney, D and West, E (1979). Effects of naproxen on connective tissue changes in the adjuvant arthritic rat. Arth Rheum, 22, 1365–74

    Article  CAS  Google Scholar 

  33. Bensley, DN and Nickander, R (1982). Comparative effects of benoxaprofen and other anti-inflammatory drugs on bone damage in the adjuvant arthritic rats. Agents & Actions, 12, 313–9

    Article  Google Scholar 

  34. Fukawa, K, Kanezuka, T. Ohba, S and Irino, O (1985). Studies on anti-inflammatory agents (5). Specific characteristic of bone changes in adjuvant arthritic rats with passage of time. Folia Pharmacol Japon, 85, 407–14

    Article  CAS  Google Scholar 

  35. Brune, K, Rainsford, KD, Wagner, K and Peskar, BA (1981). Inhibition by anti-inflammatory drugs of Prostaglandin production in cultured marcrophages. Factors influencing the apparent drug effects. Naunyn-Schmiedebergs Arch Pharmacol, 315, 269–76

    Article  PubMed  CAS  Google Scholar 

  36. Spahn, H, Thabe, K, Mutschler, E, Tillmaner, K and Gikaloo, I (1987). Concentration of azapropazone in synovial tissues and fluid. Europ J Clin Pharmacol, 32, 303–7

    Article  CAS  Google Scholar 

  37. Rainsford, KD (1985). Distribution of azapropazone and its principal 8-hydroxy-metabolite in plasma, urine and gastrointestinal mucosa determined by HPLC. J Pharm Pharmacol, 37, 341–5

    Article  PubMed  CAS  Google Scholar 

  38. Aylward, M, Bater, PA, Davies, DE, et al. (1980). Simultaneous pharmacokinetics of azapropazone in plasma and synovial fluid in patients with rheumatoid disease. Report to AH Robins (UK) study RE3/5122 [report and data on their files]

    Google Scholar 

  39. Lewis, DA, Capstick, RB and Ancill, RJ (1971). The action of azapropazone, oxyphenbutazone and Phenylbutazone on lysosomes. J Pharm Pharmacol, 23, 931–5

    Article  PubMed  CAS  Google Scholar 

  40. Mackin, WM, Ratich, SM and Marshall, CL (1986). Inhibition of rat neutrophil functional responses by azapropazone, an anti-gout drug. Biochem Pharmacol, 35, 917–22

    Article  PubMed  CAS  Google Scholar 

  41. Gans, KR, Mackin, WM and Galbraith, W (1985). Effect of azapropazone on xanthine oxidase, PMN function and macrophage arachidonate metabolism. The Pharmacoligist, 27, 243

    Google Scholar 

  42. Jahn, U and Thiele, K (1988). In vitro inhibition on xanthine oxidase by azapropazone and 8-hydroxyazapropazone. Arzneim-Forsch, 38, 507–8

    CAS  Google Scholar 

  43. Montor, SG, Thoolen, MJ, Makin, WM and Timmermans, PB (1987). Effects of azapropazone and allopurinol on myocardial infarct size in rats. Europ J Pharmacol, 140, 203–7

    Article  CAS  Google Scholar 

  44. Wagner-Janregg, Th, Burlimann, W and Fischer, J (1969). Vergleich antiphlogistischer Substanzen in Plasmaeiweiss-Trübungs-Test nach Mizushima. Arzneim-Forsch, 19, 1532–6

    Google Scholar 

  45. Urien, S., Albengres, E, Pinquier, JL and Tillerment, JP (1986). Role of alpha1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of azapropopazone and warfarin. Clin Pharmacol Ther, 39, 683–9

    Article  PubMed  CAS  Google Scholar 

  46. Mutschler, E, Jahn, U and Thiele, K (1985). 2. Positions of azapropazone relative to the category of nonsteroidal anti-rheumatic agents. In: Eberl, R and Fellmann, N (eds), Rheuma Forum Special Issue 2. (Karlsruhe: G. Braun), pp. 13–17

    Google Scholar 

  47. Jahn, U (1985). 3. Azapropazone and the problems of damage to cartilage by NSA. In: Eberl, R and Fellmann, N (eds), Rheuma Forum Special Issue 2. (Karlsruhe: G. Braun), pp. 19–23

    Google Scholar 

  48. Bostrom, H, Berntsen, K and Whitehouse, MW (1964). Biochemical properties of anti-inflammatory drugs II. Some effects on sulphate -35S metabolism in vivo. Biochem Pharmacol 13, 413–20

    Article  CAS  Google Scholar 

  49. Whitehouse, MW (1965). Some biochemical and pharmacological properties of anti-inflammatory drugs. Progress in Drug Research, 8, 321–429

    PubMed  CAS  Google Scholar 

  50. Denko, CW (1964). The effect of Phenylbutazone and its derivatives oxyphenyl-butazone and sulfinpyrazone on 35S-sulphate incorporation in cartilage and stomach. J Lab Cin Med, 63, 953–8

    CAS  Google Scholar 

  51. Kalbhen, DA, Karzel, K and Domenjoz, W (1967). The inhibitory effects of some antiphlogistic drugs on the glucosamine incorporation into mucopolysaccharides synthesized by fibroblast cultures. Med Pharmacol Exp, 16, 185–9

    CAS  Google Scholar 

  52. Kleine, TO and Hild, W (1972). Effect of anti-inflammatory drugs on the biosynthesis of Ch-4-peptides in aging bovine cartilage. Scan J Clin Lab Invest, 29, (Suppl. 123), 21

    Google Scholar 

  53. Palmoski, MJ and Brandt, KD (1980). Effects of some non-steroidal anti-inflammatory drugs on proteoglycan metabolism and organization in canine articular cartilage. Arth Rheum, 23, 1010–20

    Article  CAS  Google Scholar 

  54. Brandt, KD and Palmoski, MJ (1983). Relationships between matrix proteoglycan content and the effects of salicylate and indomethacin on articular cartilage. Arth Rheum, 26, 528–31

    Article  Google Scholar 

  55. Brandt, KD and Palmoski, MJ. Effects of salicylates and other non-steroidal anti-inflammatory drugs on articular cartilage. Am J Med, 77, 65–9

    Google Scholar 

  56. Palmoski, MJ and Brandt, KD (1985). Proteoglycan depletion, rather than fibrillation, determines the effects of salicylate and indomethacin on osteoarthritic cartilage. Arth Rheum, 28, 548–53

    Article  CAS  Google Scholar 

  57. Carney, SL (1987). A study of the effects of NSAIDs on proteoglycan metabolism in cartilage expiant cultures. In: Focus on tiaprofenac acid. Proc Int Symp on Rheumatol. Huskisson, EC and Shiokawa, Y (eds) New Trends in Rheumatology, Vol. 5. (Amsterdam: Excerpta Medica), pp. 24–34

    Google Scholar 

  58. Iwata, H (1987). Effect of anti-arthritic drugs for articular cartilage and synovial fluid. In: Focus on tiaprofenic acid. Proc Int Symp on Rheumatol, Huskisson, EC and Shiokawa, Y (eds.) New Trends in Rheumatology, Vol. 5. (Amsterdam: Excerpta Medica), pp. 35–46

    Google Scholar 

  59. McKenzie, L. Horsburgh, B and Gosh, P (1976). Effect of anti-inflammatory drugs on sulphated glycosaminoglycan synthesis in aged human articular cartilage. Ann Rheum Dis, 35, 487–97

    Article  PubMed  CAS  Google Scholar 

  60. Herman, J, Appel, A and Khosea, R (1986). The in vitro effect of select classes of non-steroidal anti-inflammatory drugs on normal cartilage metabolism. J Rheumatol, 13, 1014–8

    PubMed  CAS  Google Scholar 

  61. Palmoski, MJ and Brandt, KD (1983). Benoxoprofen stimulates proteogycan synthesis in normal canine knee cartilage in vitro. Arth Rheum, 26, 771–4

    Article  CAS  Google Scholar 

  62. Franchimont, P, Gysen, Ph, Lecomte-Yern, MJ and Malaise, M (1983). Nonsteroidal anti-inflammatory agents and articular proteoglycans. In: Tiaprofenic acid. Proc Symp Xth European Congress of Rheumatology, Moscow, 26th June-2nd July 1983. Huskisson, EC and Franchimont, P (Amsterdam: Excerpta Medica), pp. 3–14

    Google Scholar 

  63. Saxne, T, Heinegard, D and Wollheim, FA (1987). Cartilage proteoglycans in synovial fluid and serum in patients with inflammatory joint disease. Arth & Rheum, 30, 972–9

    Article  CAS  Google Scholar 

  64. Rainsford, KD, Rashad, S, Revell, P and Walker, F (1988). Effect of NSAIDs on joint arthropathy in osteoarthritic patients at arthroplasty: relation to inhibition of Prostanoids and proteoglycans. In: 4th International Meeting of the Inflammation Research Association, Abstracts, White Haven, PA

    Google Scholar 

  65. Rainsford, KD and Velo, GP (eds) (1983). Side-Effects of Anti-Inflammatory/Analgesic Drugs. (New York: Raven Press)

    Google Scholar 

  66. Rainsford, KD and Velo, GP (eds) (1987). Side-Effects of Anti-Inflammatory Drugs. Clinical and Epidemiological Agents. Pt.I. (Lancaster, UK: MTP Press)

    Google Scholar 

  67. Rainsford, KD and Velo, GP (eds) (1987). Side-Effects of Anti-Inflammatory Drugs. Studies in Major Organ Systems. Pt.II. (Lancaster, UK: MTP Press)

    Google Scholar 

  68. Rainsford, KD (1982). An analysis of the gastrointestinal side-effects of nonsteroidal anti-inflammatory drugs, with particular reference to comparative studies in man and laboratory species. Rheumatol Internat, 2, 1–10

    Article  CAS  Google Scholar 

  69. Rainsford, KD (1984). Side-effects of anti-inflammatory/analgesic drugs. Epidemiology and gastrointestinal tract. Trends in Pharmacological Sciences, 5, 156–9

    Article  CAS  Google Scholar 

  70. Rainsford, KD (1984). Side-effects of anti-inflammatory/analgesic drugs. Renal, hepatic and other systems. Trends in Pharmacological Sciences, 5, 205–8

    Article  CAS  Google Scholar 

  71. Rainsford, KD (1987). Toxicity of currently used anti-inflammatory and anti-rheumatic drugs. In: Lewis, AJ and Furst, DE (eds). Nonsteroidal Anti-inflammatory Drugs. Mechanisms and Clinical Use. (New York: Marcel Dekker) 215–244.

    Google Scholar 

  72. Rainsford, KD (1987). Side-effects of anti-inflammatory/analgesic and anti-rheumatic drugs. In: Williamson, WRN (ed), Anti-Inflammatory Drugs. (New York: Marcel Dekker) pp. 359–406

    Google Scholar 

  73. Mintz, FG and Fraga, A (1976). Gastrointestinal bleeding in patients with rheumatoid arthritis: effect of azapropazone treatment. Curr Med Res Opin 4, 89–93

    Article  PubMed  CAS  Google Scholar 

  74. Hradsky, M and Bruce, L (1987). Endoscopic evaluation of the effect of azapropazone on the gastric mucosa. Scan J Gastroenterol, 7, 31–2

    Google Scholar 

  75. Rainsford, KD (1981). Comparison of the gastric ulcerogenic activity of new non-steroidal anti-inflammatory drugs in stressed rats. Brit J Pharmacol, 73, 79c–80c

    Google Scholar 

  76. Rainsford, KD and Willis, C (1982). Relationship of gastric mucosal damage induced in pigs by anti-inflammatory drugs to their effects on Prostaglandin production. Dig Dis Sci, 27, 624–35

    Article  PubMed  CAS  Google Scholar 

  77. Rainsford, KD, Fox, SA & Osborne, DJ (1984). Comparative effects of some non-steroidal anti-inflammatory drugs on the ultrastructural integrity and Prostaglandin levels in the rat gastric mucosa. Relationship to drug uptake. Scand J Gastroenterol, 19, (Suppl. 101), 55–68

    CAS  Google Scholar 

  78. Rainsford, KD, Fox, SA and Osborne, DJ (1985). Relationship between drug absorption, inhibition of cyclooxygenase and lipoxygenase pathways and the development of gastric mucosal damage by non-steroidal anti-inflammatory drugs in rats and pigs. In: Bailey, MJ (ed), Advances in Prostaglandins, Leukotrienes and Lipoxins. (New York: Plenum Press), pp. 639–53

    Google Scholar 

  79. Rainsford, KD (1986). Structural damage and changes in eicosanoid metabolites in the gastric mucosa of rats and pigs induced by anti-inflammatory drugs in varying ulcerogenicity. Int J Tiss React, 8, 1–14

    CAS  Google Scholar 

  80. Rainsford, KD (1987). Gastric ulcerogenicity of non-steroidal anti-inflammatory drugs in mice with mucosa sensitized by cholinomimetic treatment. J Pharm Pharmacol, 39, 669–72

    PubMed  CAS  Google Scholar 

  81. Rainsford, KD (1987). Effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric mucosal lesions induced by non-steroidal anti-inflammatory drugs in cholinomimetic treated mice. Agents & Actions, 21, 316–9

    Article  CAS  Google Scholar 

  82. Rainsford, KD (1978). The effects of aspirin and other non-steroidal anti-inflammatory drugs on the gastrointestinal mucus glycoprotein biosynthesis in vivo. Relationship to ulcerogenic actions. Biochem Pharmacol, 27, 877–85

    Article  PubMed  CAS  Google Scholar 

  83. Thune, S (1976). A comparative study of azapropazone and indomethacin in the treatment of rheumatoid arthritis. Curr Med Res Opin, 4, 70–5

    Article  PubMed  CAS  Google Scholar 

  84. Thune, S (1976). Long-term use of azapropazone in the treatment of rheumatoid arthritis. Curr Med Res Opin, 4, 80–8

    Article  PubMed  CAS  Google Scholar 

  85. Diffey, BL, Pal, B and Robson, J (1986). Azapropazone therapy and photosensi-tivity. Photodermatol, 3, 304–5

    PubMed  CAS  Google Scholar 

  86. Barker, DJ and Cotterill, JA (1977). Skin eruptions due to azapropazone. Lancet, 1, 90

    Article  PubMed  CAS  Google Scholar 

  87. Barker, DJ and Cotterill, JA (1977). Azapropazone induced bullous drug eruptions. Acta Derm Venereol, 57, 461–2

    PubMed  CAS  Google Scholar 

  88. Ljunggren, B and Lundberg, K (1985). In vivo phototoxicity of non-steroidal anti-inflammatory drugs evaluated by the mouse tail technique. Photodermatol, 2, 377–88

    PubMed  CAS  Google Scholar 

  89. Llunggren, B (1985). Proprionic acid-derived non-steroidal antiinflammatory drugs are phototoxic in vitro. Photodermatol, 2, 3–9

    Google Scholar 

  90. Jones, RA, Navaratnam, S, Parsons, BJ and Phillips, GO (1988). One-electron oxidation and reduction of azapropazone and Phenylbutazone derivatives in aqueous solution: a pulse radiolysis study. Photochem Photobiol, 48, 401–8

    Article  PubMed  CAS  Google Scholar 

  91. Navaratnam, S, Hughes, JL, Parsons, BJ and Phillips GO (1985). Laser flash and steady-state photolysis of benoxaprofen in aqueous solution. Photochem Photobiol, 41, 375–80

    Article  CAS  Google Scholar 

  92. Sik, RH, Pashall, CS and Chignall, CF (1983). The phototoxic effect of benoxaprofen and its analogues on human erythrocytes and rat peritoneal mast cells. Photochem Photobiol, 38, 411–5

    Article  PubMed  CAS  Google Scholar 

  93. Reszka, K and Chignall, CG (1983). Spectroscopic studies of cutaneous photosensitizing agents—IV. The photolysis of benaxoprofen, an anti-inflammatory drug with phototoxic properties. Photochem Photobiol, 38, 281–91

    Article  PubMed  CAS  Google Scholar 

  94. Rainsford, KD (1989). Mechanism of phototoxic reactions by some NSAIDs. In preparation

    Google Scholar 

  95. Atkinson, LK, Goodship, TH and Ward, MK (1986). Acute renal failure associated with pyelonephritis and consumption of non-steroidal anti-inflammatory drugs. Br Med J, 292, 97–8

    Article  CAS  Google Scholar 

  96. Sipila, R, Skrifrars, B and Tornroth, T (1986). Reversible non-oliguric impairment of renal function during azapropazone treatment. Scand J Rheumatol, 15, 23–6

    Article  PubMed  CAS  Google Scholar 

  97. Adams, DH, Howie, AJ, Richard, J, McConkey, B, Bacon, PA and Adu, D (1986). Non-steroidal anti-inflammatory drugs and renal failure. Lancet, 1, 57–60

    Article  PubMed  CAS  Google Scholar 

  98. Templeton, JS (1978). Azapropazone and renal function. Rheumatol Rehab, 17, 219–21

    Article  CAS  Google Scholar 

  99. Jahucen, E, Blanck, KJ, Breuing, KH, Gilfrinch, HJ, Meinertz, T and Trenk, D (1981). Plasma protein binding of azapropazone in patients with kidney and liver disease. Br J Clin Pharmacol, 11, 361–7

    Google Scholar 

  100. Ritch, AE, Perera, WN and Jones, CJ (1982). Pharmacokinetics of azapropazone in the elderly. Br J Clin Pharmacol, 14, 116–9

    PubMed  CAS  Google Scholar 

  101. Lo, TC and Dymock, IW (1988). Azapropazone induced hepatitis. Br Med J, 297, 1614

    Article  CAS  Google Scholar 

  102. Williamson, PJ, Eve, MD and Roberts, CJ (1984). A study of the potential interactions between azapropazone and frusemide in man. Br J Clin Pharmacol, 18, 619–23

    PubMed  CAS  Google Scholar 

  103. Waller, DG and Waller, D (1984). Hypoglycaemia due to azapropazone — tolbutamide interaction. Br J Rheumatol, 23, 24–5

    Article  PubMed  CAS  Google Scholar 

  104. McElnay, JC and D’Arcy, PF (1978). Interaction between azapropazone and warfarin. Experientia, 34, 1320–1

    Article  PubMed  CAS  Google Scholar 

  105. McElnay, JC and D’Arcy, PF (1978). The effect of azapropazone on the binding of warfarin to human serum protein. J Pharm Pharmacol, 30 (Suppl.), 73P

    Article  Google Scholar 

  106. Faust-Tinnenfeldt, G and Gilfrich, HJ (1977). Digitoxin-Kinetik unter antirheumatischer Therapie mit azapropazone. Arzneim-Forsch, 27, 2009–11

    Google Scholar 

Download references

Authors
  1. K. D. Rainsford
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biomedical Sciences, McMaster University Faculty of Health Sciences, 1200 Main St W, Hamilton, Ontario, L8N 3Z5, Canada

    K. D. Rainsford

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Kluwer Academic Publishers

About this chapter

Cite this chapter

Rainsford, K.D. (1989). The mode of action of azapropazone in relation to its therapeutic actions in rheumatic conditions and its major side-effects. In: Rainsford, K.D. (eds) Azapropazone. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0713-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0713-3_4

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6806-2

  • Online ISBN: 978-94-009-0713-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation